Molecular Targets for Proliferative Vitreoretinopathy

REFERENCES

• Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994;14(5):417–424. doi:10.1097/00006982-199414050-00005.
   PubMed Web of Science ®Google Scholar
• Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112(2):159–165. doi:10.1016/S0002-9394(14)76695-4.
   PubMed Web of Science ®Google Scholar
• Mietz H, Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease. Br J Ophthalmol. 1995;79(10):874–877. doi:10.1136/bjo.79.10.874.
   PubMed Web of Science ®Google Scholar
• Cardillo JA, Stout JT, LaBree L, et al. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology. 1997;104(7):1166–1173. doi:10.1016/S0161-6420(97)30167-5.
   PubMed Web of Science ®Google Scholar
• Stryjewski TP, Andreoli CM, Eliott D. Retinal detachment after open globe injury. Ophthalmology. 2014;121(1):327–333. doi:10.1016/j.ophtha.2013.06.045.
   PubMed Web of Science ®Google Scholar
• Ung C, Stryjewski TP, Eliott D. Indications, findings, and outcomes of pars plana vitrectomy after open globe injury. Ophthalmol Retina. 2020;4(2):216–223. doi:10.1016/j.oret.2019.09.003.
   PubMedGoogle Scholar
• Eliott D, Stryjewski TP, Andreoli MT, Andreoli CM. Smoking is a risk factor for proliferative vitreoretinopathy after traumatic retinal detachment. Retina. 2017;37(7):1229–1235. doi:10.1097/IAE.0000000000001361.
   PubMed Web of Science ®Google Scholar
• Xu K, Chin EK, Bennett SR, et al. Predictive factors for proliferative vitreoretinopathy formation after uncomplicated primary retinal detachment repair. Retina. 2019;39(8):1488–1495. doi:10.1097/IAE.0000000000002184.
   PubMed Web of Science ®Google Scholar
• Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol. 1992;110(6):780–792. doi:10.1001/archopht.1992.01080180052028.
   PubMed Web of Science ®Google Scholar
• Bonnet M, Guenoun S. Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Graefes Arch Clin Exp Ophthalmol. 1995;233(12):789–791. doi:10.1007/BF00184091.
   PubMed Web of Science ®Google Scholar
• Laqua H, Machemer R. Clinical-pathological correlation in massive periretinal proliferation. Am J Ophthalmol. 1975;80(5):913–929. doi:10.1016/0002-9394(75)90289-5.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol. 1997;115(2):237–241. doi:10.1001/archopht.1997.01100150239014.
   PubMedGoogle Scholar
• Lei H, Rheaume MA, Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res. 2010;90(3):376–381. doi:10.1016/j.exer.2009.11.003.
   PubMed Web of Science ®Google Scholar
• Rojas J, Fernandez I, Pastor JC, et al. A strong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: the retina 4 project. Ophthalmology. 2010;117(12):2417–2423.e1-2. doi:10.1016/j.ophtha.2010.03.059.
   Web of Science ®Google Scholar
• Lumi X, Jelen MM, Jevšinek Skok D, et al. Comparison of SNP genotypes related to proliferative vitreoretinopathy (PVR) across Slovenian and European Subpopulations. J Ophthalmol. 2018;2018:8761625. doi:10.1155/2018/8761625.
   PubMed Web of Science ®Google Scholar
• Pastor-Idoate S, Rodríguez-Hernández I, Rojas J, et al. Group, G. o. P. S., The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy. PLoS One. 2013;8(12):e82283. doi:10.1371/journal.pone.0082283.
   PubMed Web of Science ®Google Scholar
• Pastor-Idoate S, Rodriguez-Hernández I, Rojas J, et al. Group*, G. o. P. S., The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: the Retina 4 Project. Ophthalmology. 2013;120(3):623–628. doi:10.1016/j.ophtha.2012.08.019.
   PubMed Web of Science ®Google Scholar
• Pastor-Idoate S, Rodríguez-Hernández I, Rojas J, et al. Group, G. o. P. S., BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: the Retina 4 project. Acta Ophthalmol. 2015;93(7):e541–9. doi:10.1111/aos.12718.
   PubMed Web of Science ®Google Scholar
• Yu J, Peng R, Chen H, Cui C, Ba J. Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis. Invest Ophthalmol Vis Sci. 2012;53(13):8146–8153. doi:10.1167/iovs.12-10079.
   PubMed Web of Science ®Google Scholar
• Storey P, Alshareef R, Khuthaila M, et al. Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy. Retina. 2014;34(10):1945–1951. doi:10.1097/IAE.0000000000000216.
   PubMed Web of Science ®Google Scholar
• Narala R, Nassiri N, Kim C, Mehregan C, Padidam S, Abrams GW. Outcomes of repeat pars plana vitrectomy after failed surgery for proliferative vitreoretinopathy. Retina. 2018;38(Suppl 1):S49–S59. doi:10.1097/IAE.0000000000002000.
   PubMedGoogle Scholar
• Furino C, Micelli Ferrari T, Boscia F, Cardascia N, Recchimurzo N, Sborgia C. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina. 2003;23(6):771–776. doi:10.1097/00006982-200312000-00004.
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology. 2008;115(11):1938–1943. doi:10.1016/j.ophtha.2008.05.016.
   PubMed Web of Science ®Google Scholar
• Banerjee PJ, Quartilho A, Bunce C, et al. Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology. 2017;124(6):757–767. doi:10.1016/j.ophtha.2017.01.021.
   PubMed Web of Science ®Google Scholar
• Koerner F, Koerner-Stiefbold U, Garweg JG. Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial. Graefes Arch Clin Exp Ophthalmol. 2012;250(7):981–987. doi:10.1007/s00417-011-1919-y.
   PubMed Web of Science ®Google Scholar
• Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand Khani A. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye (Lond). 2014;28(5):576–580. doi:10.1038/eye.2014.21.
   PubMed Web of Science ®Google Scholar
• Hsu J, Khan MA, Shieh WS, et al. Effect of serial intrasilicone oil bevacizumab injections in eyes with recurrent proliferative vitreoretinopathy retinal detachment. Am J Ophthalmol. 2016;161:65–70.e1-2. doi:10.1016/j.ajo.2015.09.029.
   Web of Science ®Google Scholar
• Zhao XY, Xia S, Wang EQ, Chen YX. Efficacy of intravitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreoretinopathy retinal detachment: a meta-analysis of prospective studies. Retina. 2018;38(3):462–470. doi:10.1097/IAE.0000000000001584.
   PubMed Web of Science ®Google Scholar
• Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg. 1989;20:268–272.
   PubMedGoogle Scholar
• Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126(4):550–559. doi:10.1016/S0002-9394(98)00115-9.
   PubMed Web of Science ®Google Scholar
• Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108(7):1179–1183. doi:10.1016/S0161-6420(01)00589-9.
   PubMed Web of Science ®Google Scholar
• Garcia RA, Sanchez JG, Arevalo JF. Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C. Ophthalmic Surg Lasers Imaging. 2007;38(4):276–282. doi:10.3928/15428877-20070701-02.
   PubMedGoogle Scholar
• Amarnani D, Machuca-Parra AI, Wong LL, et al. Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2017;58(10):3940–3949. doi:10.1167/iovs.16-20912.
   PubMed Web of Science ®Google Scholar
• Eliott D, Methotrexate for the prevention of PVR: a phase 1 study. In VAIL VITRECTOMY MEETING, Vail, CO, Feb 20, 2016.
   Google Scholar
• The GUARD Trial - Part 1: a Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for prevention of proliferative vitreoretinopathy. ClinicalTrials.gov NCT04136366.
   Google Scholar
• Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 2016;10:1811–1817.
   PubMed Web of Science ®Google Scholar
• Nourinia R, Borna F, Rahimi A, et al. Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy: a pilot study. Ophthalmologica. 2019;242(2):113–117. doi:10.1159/000500271.
   PubMed Web of Science ®Google Scholar
• Denstedt J, Schulz DC, Diaconita V, Sheidow TG. Acupuncture resulting in eye penetration and proliferative vitreoretinopathy - Surgical and medical management with intraocular methotrexate. Am J Ophthalmol Case Rep. 2020;18:100605. doi:10.1016/j.ajoc.2020.100605.
   PubMedGoogle Scholar
• Fekrat S, De Juan E, Campochiaro PA. The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology. 1995;102(3):412–418. doi:10.1016/S0161-6420(95)31007-X.
   PubMed Web of Science ®Google Scholar
• Chang YC, Hu DN, Wu WC. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmol. 2008;146(3):440–446. doi:10.1016/j.ajo.2008.05.002.
   PubMed Web of Science ®Google Scholar
• London NJS, Kaiser RS, Khan MA, et al. Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the Deliver trial. Br J Ophthalmol. 2019;103(9):1306–1313. doi:10.1136/bjophthalmol-2018-312839.
   PubMed Web of Science ®Google Scholar
• Schiff WM, Hwang JC, Ober MD, et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol. 2007;125(9):1161–1167. doi:10.1001/archopht.125.9.1161.
   PubMedGoogle Scholar
• Zheng Y, Ikuno Y, Ohj M, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol. 2003;47(2):158–165. doi:10.1016/S0021-5155(02)00698-6.
   PubMed Web of Science ®Google Scholar
• Abdullatif AM, Macky TA, Abdullatif MM, et al. Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2018;256(12):2473–2481. doi:10.1007/s00417-018-4105-7.
   PubMed Web of Science ®Google Scholar
• Cui L, Lyu Y, Jin X, et al. miR-194 suppresses epithelial-mesenchymal transition of retinal pigment epithelial cells by directly targeting ZEB1. Ann Transl Med. 2019;7(23):751. doi:10.21037/atm.2019.11.90.
   PubMed Web of Science ®Google Scholar
• Lyu Y, Xu W, Zhang J, et al. Protein Kinase A Inhibitor H89 attenuates experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2020;61(2):1. doi:10.1167/iovs.61.2.1.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Choi KS, Warther D, et al. A sustained dual drug delivery system for proliferative vitreoretinopathy. Drug Deliv. 2020;27(1):1461–1473. doi:10.1080/10717544.2020.1833382.
   PubMed Web of Science ®Google Scholar